InflaRx Secures Funding Through 2029, Advances Izicopan in AAV and Renal Diseases
IFRX•InflaRx plans Phase 2 trials of oral C5a receptor inhibitor izicopan in ANCA-associated vasculitis while exploring expedited regulatory pathways against avacopan. The company aims to initiate proof-of-concept studies next year in aHUS, IgA nephropathy and C3 glomerulopathy and expects funding through 2029 to support development.
1. Izicopan Development in AAV
InflaRx is advancing izicopan, an oral C5aR inhibitor, into Phase 2 trials for ANCA-associated vasculitis and is evaluating expedited regulatory strategies to position it against the approved comparator avacopan.
2. Expansion into Complement-Mediated Renal Diseases
The company plans open-label proof-of-concept studies in atypical hemolytic uremic syndrome, IgA nephropathy and C3 glomerulopathy, with clinical data expected next year to validate izicopan’s differentiated profile in life-threatening renal disorders.
3. Financial Runway and Funding
InflaRx reports sufficient cash to fund its currently planned clinical programs and operations through 2029, covering Phase 2 data readouts in AAV and proof-of-concept results in aHUS, IgAN and C3G without incremental financing.
4. Upcoming Capital Markets Day and Webcast
A Capital Markets Day is scheduled for summer 2026 to outline izicopan’s best-in-class potential across four indications, and a webcast on May 8 will review the new strategy for AAV and renal disease development.
